Skip to main content
TipRanks
Go Ultimate75% OFF

Inhibikase Therapeutics (IKT) Cash flow

380 Followers

Inhibikase Therapeutics Cash Flow

IKT's free cash flow for Q3 2026 was $-17.35M. For the 2026 fiscal year, IKT's free cash flow was increased by $0.00 and operating cash flow was $-17.35M. See a summary of the company’s cash flow.

Cash Flow
Cash FlowDec 25Dec 24Dec 23Mar 23Mar 22
$ -27.79M$ -19.15M$ -18.09M$ -17.35M$ -14.30M
$ 2.05M$ -37.00M$ 11.66M$ -16.01M$ 0.00
$ 108.46M$ 103.48M$ 8.41M$ -204.77K$ 41.09M
$ 139.22M$ 56.49M$ 9.17M$ 7.19M$ 40.75M
$ -27.79M$ -19.15M$ -18.10M$ -17.59M$ -14.30M

Currency in USD

Inhibikase Therapeutics Cash Flow

-50M050M100M150M201720182019202020212022202320242025OperatingInvestingFinancing